OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics, Inc. The company was founded in 2009 and is headquartered in Irvine, California.
IPO Year:
Exchange: AMEX
Website: oncocyte.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/28/2025 | $5.00 | Buy | Lake Street |
| 5/24/2022 | Overweight → Equal-Weight | Stephens | |
| 3/14/2022 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 3/11/2022 | $11.00 → $6.00 | Buy | Lake Street |
| 3/11/2022 | $5.00 → $4.00 | Buy | Needham |
| 1/7/2022 | $3.10 | Overweight | Stephens & Co. |
| 1/6/2022 | $3.10 | Overweight | Piper Sandler |
| 12/16/2021 | $7.00 → $5.00 | Buy | Needham |
| 11/10/2021 | $8.00 → $7.00 | Buy | Needham |